Back to search results
NCT06772181

A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
University of Washington
~40 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:IM@Home ProgramMedical Device Usage and EvaluationQuestionnaire AdministrationInterview

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of eligible patients that consent to the screening registry (Feasibility)
Measured over Up to 6 months
+2 more outcomes measured

Conditions

Breast Carcinoma

Explore related trials

Breast Carcinoma

Where it's being run

2 sites across 1 states
Washington2

Study leadership

  • Erin Gillespie, MD, MPH · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years old.
Ability to understand English, or has a caregiver who understands English.
Ability to understand and willingness to sign a written informed consent document, virtually or in-person.
Current breast cancer diagnosis.
Currently receiving radiation with curative intent (including partial breast, whole breast, or regional nodal radiation).

Exclusion

Patients who are non-English speaking that would prevent their participation in IM@Home.

What this trial measures

  • Proportion of eligible patients that consent to the screening registry (Feasibility)Up to 6 months

    Will be considered feasible, as designed, if over 50% of eligible patients consent to the screening registry. Will be determined using descriptive statistics.

  • Proportion of patients with fatigue or other comorbid symptoms enrolling to the Integrative Medicine at Home (IM@Home) virtual intervention (Acceptability)Up to 6 months

    Will be considered acceptable if 50% of patients reporting fatigue or other comorbid symptoms agree to enroll to the IM@Home intervention. Will be determined using descriptive statistics.

  • Proportion of patients enrolling in IM@Home virtual intervention that report favorable implementation outcomes (Appropriateness)At 12 weeks

    Will be assessed using a validated patient-reported outcomes (PRO) scale with responses as agree or completely agree. Will be determined using descriptive statistics.